Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. (Nasdaq: ICCM) is a foreign private issuer that files reports with the U.S. Securities and Exchange Commission (SEC) in connection with its liquid-nitrogen-based cryoablation systems for tumor destruction. On this page, you can review IceCure’s SEC filings, including current reports on Form 6-K that furnish press releases about regulatory milestones, clinical data, commercial progress, and corporate actions.
IceCure’s Form 6-K filings often incorporate press releases by reference into its registration statements on Form F-3 and Form S-8. These filings cover topics such as U.S. Food and Drug Administration (FDA) marketing authorization for the ProSense® Cryoablation System in low-risk breast cancer for women aged 70 and above, regulatory approvals for ProSense® in Switzerland and other markets, notices of patent allowance for technologies like cryogen flow control related to the next-generation XSense™ system, and financial and operational results for specified reporting periods.
Filings also document corporate developments, including changes in management roles and Nasdaq notifications regarding minimum bid price compliance. By reviewing these documents, investors can see how IceCure describes its minimally invasive cryoablation technology, its primary focus areas in breast, kidney, bone, and lung cancer, and the regulatory and commercial steps it reports taking to expand use of ProSense® and XSense™.
Stock Titan’s SEC filings page presents IceCure’s submissions as they are made available on EDGAR and enhances accessibility with AI-powered summaries. These summaries are designed to highlight key points from lengthy documents, such as the nature of a regulatory authorization, the scope of a patent allowance, or the main elements of a financial update. Users can quickly identify filings related to clinical milestones, regulatory approvals, capital markets activity, and other material events disclosed by IceCure Medical Ltd.
IceCure Medical Ltd. filed a Form 6-K as a foreign private issuer, providing investors with a package of information on its performance for the first half of 2025. The report furnishes unaudited interim condensed consolidated financial statements as of and for the six months ended June 30, 2025.
It also includes management’s discussion and analysis of financial condition and results of operations for the same period, plus a press release titled “IceCure Reports Financial & Operational Results for the First Half of 2025.” These materials are incorporated by reference into existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. (ICCM) filed a Form 6-K to furnish materials for a Special General Meeting of Shareholders scheduled for 1 September 2025. Shareholders of record at the close of business on 4 August 2025 are entitled to receive notice and vote. The filing attaches three exhibits: (i) Notice of Meeting, (ii) Proxy Statement, and (iii) Proxy Card. No financial statements, earnings figures, or transaction details are included. The 6-K is incorporated by reference into the company’s effective shelf (F-3) and equity compensation (S-8) registration statements.